DPC 684 

DPC 684 is a potent and selective HIV-1 protease inhibitor (IC₉₀ = 5.7-40 nM, Ki = 0.021 nM). DPC 684 competitively inhibits HIV-1 protease and blocks viral polyprotein cleavage. DPC 684 has low protein binding and broad-spectrum inhibition against a variety of wild-type and mutant HIV-1 proteases. DPC 684 has low protein binding and broad-spectrum inhibition (IC₉₀ = 1.9-6.3 nM). DPC 684 has research significance for HIV^[1].

DPC 684 (Compound DPC 684) exhibits broad-spectrum anti-HIV-1 activity, requiring an average concentration of 14.5 nM for 90% inhibition of viral replication across cell models (MT-2: HIV-1 RF, IIIB strains; PBMC: HIV-1 IIIB, NL4-3 strains)^[1].

DPC 684 exhibits antiviral activity against laboratory and clinical isolates (IC₉₀: 5.7 nM, 7.8 nM for RF; 12 nM for HXB2; 20 nM for NL4-3; 8.8 nM, 40 nM for IIIB; 11 nM for Thai 9466 and Patient E; 32 nM for HIV-2)^[1].

DPC 684 maintains high efficacy against common clinical drug-resistant mutations in MT-2 cells, with an IC₉₀ of 8.8 nM for the D30N mutation (no loss of potency) and 26 nM for multiple mutations (2-fold reduction in potency)^[1].

DPC 684 does not significantly inhibit 17 human proteases (including renin and pepsin) at a concentration of 13 μM, demonstrating its high selectivity for HIV protease^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DPC 684 (Compound DPC 684) induces histological changes in the liver of rats and mild first-degree atrioventricular block in dogs on electrocardiogram in a 2-week safety evaluation study in rats and dogs, and the potential risks to these target organs require special attention when advancing research^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

669.85

C₃₅H₄₈FN₅O₅S

284661-73-0

O=S(N(CC(C)C)C[C@@H](O)[C@@H](NC([C@H](C(C)(C)C)NC(CNCC1=CC(F)=CC=C1)=O)=O)CC2=CC=CC=C2)(C3=CC=C(C=C3)N)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. R F Kaltenbach 3rd, et al. DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants. Antimicrob Agents Chemother. 2001 Nov;45(11):3021-8.  [Content Brief]